Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for MIRM

Stock Name	Mirum Pharmaceuticals Inc
Ticker	MIRM(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US6047491013

Show aggregate MIRM holdings

News associated with MIRM

Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $74.44: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price […] - 2025-09-19 02:26:46
Mirum Pharmaceuticals (NASDAQ:MIRM) Lowered to Buy Rating by Wall Street Zen: Wall Street Zen lowered shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) from a strong-buy rating to a buy rating in a research note released on Monday morning. Other analysts have also recently issued research reports about the stock. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note […] - 2025-08-26 03:03:11
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Strong-Buy: Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Sunday. A number of other equities analysts also recently weighed in on the stock. JMP Securities set a $81.00 target price […] - 2025-08-19 02:58:52
Deutsche Bank AG Buys 71,421 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Deutsche Bank AG grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 42.2% during the first quarter, Holdings Channel reports. The firm owned 240,744 shares of the company’s stock after purchasing an additional 71,421 shares during the period. Deutsche Bank AG’s holdings in Mirum Pharmaceuticals were worth $10,846,000 as of its most […] - 2025-08-15 05:22:53
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Upgraded by Wall Street Zen: Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) from a hold rating to a buy rating in a research report released on Saturday morning. Several other research analysts have also commented on the stock. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave […] - 2025-08-12 04:48:59
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 9.1% on Analyst Upgrade: Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) were up 9.1% during trading on Monday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $65.31 and last traded at $65.41. Approximately 671,423 shares traded hands during mid-day trading, an increase of […] - 2025-08-12 02:18:51
Zurcher Kantonalbank Zurich Cantonalbank Boosts Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 3.8% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,998 shares of the company’s stock after purchasing an additional 398 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Mirum Pharmaceuticals were worth $495,000 […] - 2025-08-08 04:48:50
Cwm LLC Boosts Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Cwm LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 259.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 593 shares of the company’s stock after buying an additional 428 shares during the quarter. Cwm LLC’s holdings in Mirum Pharmaceuticals were worth $27,000 at the end of the most […] - 2025-08-06 04:24:52
Bank of New York Mellon Corp Buys 122,402 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Bank of New York Mellon Corp boosted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 98.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 246,730 shares of the company’s stock after purchasing an additional 122,402 shares during the […] - 2025-07-21 04:26:48
Allspring Global Investments Holdings LLC Sells 1,195 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Allspring Global Investments Holdings LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 12.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,786 shares of the company’s stock after selling 1,195 shares during the period. Allspring […] - 2025-07-11 04:36:57
KBC Group NV Makes New $89,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): KBC Group NV acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,967 shares of the company’s stock, valued at approximately $89,000. Other hedge funds have also added to or […] - 2025-07-08 04:42:53
Mirum Pharmaceuticals (NASDAQ:MIRM) Lowered to Hold Rating by Wall Street Zen: Wall Street Zen downgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) from a buy rating to a hold rating in a research note published on Sunday morning. MIRM has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Mirum […] - 2025-07-07 03:22:59
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $60.73 Consensus Target Price from Analysts: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […] - 2025-06-11 02:22:45
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 16.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,888 shares of the company’s stock after acquiring an additional […] - 2025-06-06 04:42:48
ProShare Advisors LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): ProShare Advisors LLC grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 31.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,457 shares of the company’s stock after acquiring an additional 3,227 shares during […] - 2025-05-26 06:09:07
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $1.01 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,327 shares of the company’s stock after selling 498 shares during the quarter. MIRAE […] - 2025-05-26 04:38:55
Nuveen Asset Management LLC Has $29.86 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Nuveen Asset Management LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 46.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 722,155 shares of the company’s stock after buying an additional 229,746 shares during the quarter. Nuveen Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $29,861,000 as of […] - 2025-05-22 06:38:53
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLC: Millennium Management LLC grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 15.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 526,974 shares of the company’s stock after acquiring an additional 71,410 shares during the quarter. Millennium Management LLC owned about 1.10% […] - 2025-05-21 05:46:51
HC Wainwright Reiterates Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM): Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $73.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 61.01% from the company’s current price. […] - 2025-05-21 03:03:17
Comerica Bank Decreases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Comerica Bank lessened its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 76.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 617 shares of the company’s stock after selling 1,971 shares during the period. Comerica Bank’s […] - 2025-05-20 04:28:52
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $58.20: Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have been given an average recommendation of “Buy” by the eleven ratings firms that are covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 […] - 2025-04-22 02:34:59
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $58.20 Consensus Target Price from Analysts: Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price […] - 2025-03-28 03:34:46
AlphaQuest LLC Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,829 shares of the company’s stock after acquiring an additional 1,658 shares during the quarter. AlphaQuest LLC’s holdings in […] - 2025-03-20 06:04:50
Bank of New York Mellon Corp Has $5.14 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Bank of New York Mellon Corp grew its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 8.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 124,328 shares of the company’s stock after acquiring an additional 9,629 shares during the period. Bank of New York Mellon Corp’s holdings in Mirum Pharmaceuticals were […] - 2025-03-18 05:09:03
Empowered Funds LLC Invests $1.38 Million in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Empowered Funds LLC acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 33,266 shares of the company’s stock, valued at approximately $1,376,000. A number of other large investors […] - 2025-02-17 06:16:48
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $57.10: Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-02-06 04:24:49

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc MIRM holdings

Date	Number of MIRM Shares Held	Base Market Value of MIRM Shares	Local Market Value of MIRM Shares	Change in MIRM Shares Held	Change in MIRM Base Value	Current Price per MIRM Share Held	Previous Price per MIRM Share Held
2025-09-29 (Monday)	4,556	USD 331,905	USD 331,905
2025-09-26 (Friday)	4,556	USD 331,495	USD 331,495
2025-09-25 (Thursday)	4,556	USD 335,185	USD 335,185	0	USD -3,144	USD 73.57	USD 74.2601
2025-09-24 (Wednesday)	4,556	USD 338,329	USD 338,329
2025-09-17 (Wednesday)	4,528	USD 331,178	USD 331,178	0	USD -2,943	USD 73.14	USD 73.79
2025-09-16 (Tuesday)	4,528	USD 334,121	USD 334,121
2025-09-12 (Friday)	4,500	USD 334,395	USD 334,395
2025-09-11 (Thursday)	4,500	USD 341,955	USD 341,955

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MIRM by Blackrock for IE00B3VWM098

Show aggregate share trades of MIRM

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -10 69.060* 45.99 Profit of 460 on sale
2025-07-31 BUY 30 51.680* 45.83
2025-06-30 SELL -20 50.890* 45.10 Profit of 902 on sale
2025-06-25 SELL -10 50.130* 44.99 Profit of 450 on sale
2025-06-20 SELL -20 50.340* 44.87 Profit of 897 on sale
2025-05-23 BUY 10 44.000* 44.54
2025-05-19 SELL -10 44.890* 44.54 Profit of 445 on sale
2025-05-15 SELL -30 45.280* 44.53 Profit of 1,336 on sale
2025-05-12 SELL -10 45.570* 44.51 Profit of 445 on sale
2025-05-09 SELL -10 44.270* 44.51 Profit of 445 on sale
2025-04-30 SELL -10 43.450* 44.60 Profit of 446 on sale
2025-04-24 SELL -20 40.470* 44.74 Profit of 895 on sale
2025-04-17 SELL -10 39.100* 45.04 Profit of 450 on sale
2025-04-15 SELL -30 38.630* 45.17 Profit of 1,355 on sale
2025-04-14 SELL -30 39.590* 45.24 Profit of 1,357 on sale
2025-04-09 SELL -40 41.470* 45.41 Profit of 1,817 on sale
2025-04-07 SELL -70 41.000* 45.53 Profit of 3,187 on sale
2025-04-04 SELL -100 42.030* 45.58 Profit of 4,558 on sale
2025-03-31 BUY 10 45.050* 45.61
2025-03-19 SELL -20 47.130* 45.48 Profit of 910 on sale
2025-03-14 SELL -60 44.280* 45.52 Profit of 2,731 on sale
2025-03-13 SELL -20 44.560* 45.53 Profit of 911 on sale
2025-03-12 SELL -340 45.030* 45.54 Profit of 15,483 on sale
2025-03-07 SELL -20 43.460* 45.63 Profit of 913 on sale
2025-03-06 SELL -30 43.420* 45.66 Profit of 1,370 on sale
2025-03-03 SELL -10 45.990* 45.68 Profit of 457 on sale
2025-02-28 SELL -60 47.570* 45.65 Profit of 2,739 on sale
2025-02-26 SELL -10 50.520* 45.55 Profit of 455 on sale
2025-02-25 SELL -30 49.930* 45.47 Profit of 1,364 on sale
2025-02-18 BUY 50 52.700* 44.83
2025-02-13 BUY 10 50.700* 44.50
2025-02-12 BUY 10 50.720* 44.38
2025-02-11 BUY 30 50.160* 44.25
2025-02-06 BUY 90 51.230* 43.81
2025-01-27 BUY 10 48.480* 42.63
2024-12-30 BUY 50 41.180* 42.37
2024-12-06 BUY 40 44.670* 42.20
2024-12-05 BUY 10 44.400* 42.12
2024-12-04 BUY 50 45.470* 42.00
2024-11-29 BUY 50 46.220* 41.52
2024-11-27 BUY 40 46.650* 41.08
2024-11-26 BUY 10 45.150* 40.89
2024-11-21 BUY 50 43.480* 40.38
2024-11-20 BUY 30 43.690* 40.19
2024-11-18 BUY 120 41.420* 40.00
2024-11-12 BUY 80 42.280* 39.85
2024-11-08 BUY 50 42.000* 39.69
2024-11-07 BUY 150 41.080* 39.58
2024-11-06 BUY 20 41.090* 39.46
2024-10-31 BUY 10 38.460* 39.18
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-10	69.060*	45.99 Profit of 460 on sale
2025-07-31	BUY	30	51.680*	45.83
2025-06-30	SELL	-20	50.890*	45.10 Profit of 902 on sale
2025-06-25	SELL	-10	50.130*	44.99 Profit of 450 on sale
2025-06-20	SELL	-20	50.340*	44.87 Profit of 897 on sale
2025-05-23	BUY	10	44.000*	44.54
2025-05-19	SELL	-10	44.890*	44.54 Profit of 445 on sale
2025-05-15	SELL	-30	45.280*	44.53 Profit of 1,336 on sale
2025-05-12	SELL	-10	45.570*	44.51 Profit of 445 on sale
2025-05-09	SELL	-10	44.270*	44.51 Profit of 445 on sale
2025-04-30	SELL	-10	43.450*	44.60 Profit of 446 on sale
2025-04-24	SELL	-20	40.470*	44.74 Profit of 895 on sale
2025-04-17	SELL	-10	39.100*	45.04 Profit of 450 on sale
2025-04-15	SELL	-30	38.630*	45.17 Profit of 1,355 on sale
2025-04-14	SELL	-30	39.590*	45.24 Profit of 1,357 on sale
2025-04-09	SELL	-40	41.470*	45.41 Profit of 1,817 on sale
2025-04-07	SELL	-70	41.000*	45.53 Profit of 3,187 on sale
2025-04-04	SELL	-100	42.030*	45.58 Profit of 4,558 on sale
2025-03-31	BUY	10	45.050*	45.61
2025-03-19	SELL	-20	47.130*	45.48 Profit of 910 on sale
2025-03-14	SELL	-60	44.280*	45.52 Profit of 2,731 on sale
2025-03-13	SELL	-20	44.560*	45.53 Profit of 911 on sale
2025-03-12	SELL	-340	45.030*	45.54 Profit of 15,483 on sale
2025-03-07	SELL	-20	43.460*	45.63 Profit of 913 on sale
2025-03-06	SELL	-30	43.420*	45.66 Profit of 1,370 on sale
2025-03-03	SELL	-10	45.990*	45.68 Profit of 457 on sale
2025-02-28	SELL	-60	47.570*	45.65 Profit of 2,739 on sale
2025-02-26	SELL	-10	50.520*	45.55 Profit of 455 on sale
2025-02-25	SELL	-30	49.930*	45.47 Profit of 1,364 on sale
2025-02-18	BUY	50	52.700*	44.83
2025-02-13	BUY	10	50.700*	44.50
2025-02-12	BUY	10	50.720*	44.38
2025-02-11	BUY	30	50.160*	44.25
2025-02-06	BUY	90	51.230*	43.81
2025-01-27	BUY	10	48.480*	42.63
2024-12-30	BUY	50	41.180*	42.37
2024-12-06	BUY	40	44.670*	42.20
2024-12-05	BUY	10	44.400*	42.12
2024-12-04	BUY	50	45.470*	42.00
2024-11-29	BUY	50	46.220*	41.52
2024-11-27	BUY	40	46.650*	41.08
2024-11-26	BUY	10	45.150*	40.89
2024-11-21	BUY	50	43.480*	40.38
2024-11-20	BUY	30	43.690*	40.19
2024-11-18	BUY	120	41.420*	40.00
2024-11-12	BUY	80	42.280*	39.85
2024-11-08	BUY	50	42.000*	39.69
2024-11-07	BUY	150	41.080*	39.58
2024-11-06	BUY	20	41.090*	39.46
2024-10-31	BUY	10	38.460*	39.18

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MIRM

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	72,234	12,268	239,583	30.1%
2025-09-18	56,289	4,189	270,196	20.8%
2025-09-17	63,196	2,072	246,781	25.6%
2025-09-16	51,643	737	135,386	38.1%
2025-09-15	64,888	1,194	154,251	42.1%
2025-09-12	57,160	4,688	134,198	42.6%
2025-09-11	70,286	15,334	174,511	40.3%
2025-09-10	82,464	5,085	167,281	49.3%
2025-09-09	73,988	834	336,086	22.0%
2025-09-08	97,340	13,009	164,656	59.1%
2025-09-05	80,692	16,260	182,480	44.2%
2025-09-04	78,856	4,815	267,458	29.5%
2025-09-03	107,413	6,645	236,559	45.4%
2025-09-02	93,337	13,124	262,898	35.5%
2025-08-29	121,904	48,466	300,335	40.6%
2025-08-28	1,070,514	487,947	1,261,346	84.9%
2025-08-27	178,887	15,088	336,545	53.2%
2025-08-26	162,362	47,309	392,103	41.4%
2025-08-25	152,416	11,814	376,254	40.5%
2025-08-22	239,539	18,239	501,022	47.8%
2025-08-21	102,778	1,810	220,353	46.6%
2025-08-20	65,999	15,860	117,614	56.1%
2025-08-19	109,840	23,102	254,294	43.2%
2025-08-18	143,781	13,657	280,969	51.2%
2025-08-15	143,436	7,364	448,893	32.0%
2025-08-14	135,036	152	253,879	53.2%
2025-08-13	142,034	13,145	401,031	35.4%
2025-08-12	204,950	18,158	529,102	38.7%
2025-08-11	547,438	66,339	931,938	58.7%
2025-08-08	130,750	16,423	382,752	34.2%
2025-08-07	516,882	25,348	928,076	55.7%
2025-08-06	128,256	184	252,662	50.8%
2025-08-05	78,055	14	157,095	49.7%
2025-08-04	43,796	60	120,847	36.2%
2025-08-01	52,940	79	107,267	49.4%
2025-07-31	55,097	0	107,016	51.5%
2025-07-30	43,200	0	115,799	37.3%
2025-07-29	68,753	0	113,923	60.4%
2025-07-28	36,200	19	54,133	66.9%
2025-07-25	58,369	8	87,772	66.5%
2025-07-24	65,168	33	94,132	69.2%
2025-07-23	135,117	183	188,922	71.5%
2025-07-22	76,666	0	101,231	75.7%
2025-07-21	61,211	389	96,968	63.1%
2025-07-18	28,143	0	61,650	45.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE